Core Insights - Kintor Pharmaceutical's CT0596 shows promising results in early clinical trials for relapsed/refractory multiple myeloma patients, demonstrating strong anti-tumor activity and good safety profiles [2][3] Clinical Trial Results - The Phase I clinical trial included 8 patients with a median of 4.5 prior treatment lines, indicating a complex and heavily pre-treated population [2] - Overall response rate is high, with 6 out of 8 evaluable patients achieving partial response (PR) or better; 5 of 6 patients receiving full-dose lymphodepletion achieved PR or better, all reaching minimal residual disease (MRD) negativity by week 4 [3] - Three patients achieved stringent complete response (sCR), with one patient maintaining sCR and MRD negativity at 8 months [3] Safety Profile - CT0596 exhibited excellent safety characteristics, with only 4 patients experiencing grade 1 cytokine release syndrome (CRS) and no severe CRS observed [4] - No immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GVHD) was reported, and no dose-limiting toxicities were observed [4] Future Plans - The trial is still in the dose exploration phase, with plans to explore higher cell dosing to determine the recommended dose [4] - The company aims to initiate Phase IB registration clinical studies for CT0596 in 2026 based on encouraging preliminary data [4]
科济药业：通用型CAR-T产品CT0596公布最新数据